GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BetterLife Pharma Inc (XCNQ:BETR) » Definitions » 3-Year FCF Growth Rate

BetterLife Pharma (XCNQ:BETR) 3-Year FCF Growth Rate : 68.80% (As of Oct. 2023)


View and export this data going back to 2017. Start your Free Trial

What is BetterLife Pharma 3-Year FCF Growth Rate?

BetterLife Pharma's Free Cash Flow per Share for the three months ended in Oct. 2023 was C$-0.00.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was 68.80% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was 29.20% per year. During the past 10 years, the average Free Cash Flow per Share Growth Rate was -39.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

During the past 13 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of BetterLife Pharma was 68.80% per year. The lowest was -176.90% per year. And the median was -22.85% per year.


Competitive Comparison of BetterLife Pharma's 3-Year FCF Growth Rate

For the Biotechnology subindustry, BetterLife Pharma's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BetterLife Pharma's 3-Year FCF Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BetterLife Pharma's 3-Year FCF Growth Rate distribution charts can be found below:

* The bar in red indicates where BetterLife Pharma's 3-Year FCF Growth Rate falls into.



BetterLife Pharma 3-Year FCF Growth Rate Calculation

This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.


BetterLife Pharma  (XCNQ:BETR) 3-Year FCF Growth Rate Explanation

Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.


BetterLife Pharma 3-Year FCF Growth Rate Related Terms

Thank you for viewing the detailed overview of BetterLife Pharma's 3-Year FCF Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


BetterLife Pharma (XCNQ:BETR) Business Description

Traded in Other Exchanges
Address
1275 West 6th Avenue, Suite 300, Vancouver, BC, CAN, V6H 1A6
BetterLife Pharma Inc a biotechnology company, engages in the development and commercialization of psychedelic products for the treatment of mental disorders in Canada, the United States, Australia, and European Union. It is involved in refining and developing drug candidates from a set of complementary interferon-based technologies that have the potential to engage the immune system to fight virus infections, such as coronavirus disease and human papillomavirus, and/or to directly inhibit tumors to treat various types of cancer.
Executives
Ahmad Doroudian Director, Senior Officer